Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic activation and tissue infiltration of CD8 + CX3CR1 + T cells in non-small cell lung cancer treated with neoadjuvant immune checkpoint blockade.

British journal of cancer·2025
Same author

KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.

Angiogenesis·2025
Same author

Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study.

International journal of cancer·2025
Same author

Development and validation of machine learning models based on molecular features for estimating the probability of multiple primary lung carcinoma versus intrapulmonary metastasis in patients presenting multiple non-small cell lung cancers.

Translational lung cancer research·2025
Same author

Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.

Cancer cell international·2025
Same author

Neoadjuvant adebrelimab combined with chemotherapy (cisplatin/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS).

BMJ open·2025

Related Experiment Video

Updated: Oct 2, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

[Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].

Chunlu Shu1, Daxing Zhu2, Qinghua Zhou2

  • 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation 
Center, Chengdu 610041, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|February 28, 2022
PubMed
Summary

Neoadjuvant immune checkpoint inhibitors (ICIs) show promise for resectable non-small cell lung cancer (NSCLC) by improving outcomes. Identifying predictive biomarkers is crucial for selecting patients who will benefit most from these novel therapies.

Keywords:
BiomarkersImmune checkpoint inhibitorLung neoplasmsNeoadjuvant therapy

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K

Related Experiment Videos

Last Updated: Oct 2, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Surgery

Background:

  • Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC).
  • Neoadjuvant and adjuvant therapies are employed to prevent cancer recurrence and metastasis.
  • Immune checkpoint inhibitors (ICIs) have demonstrated significant survival benefits in advanced NSCLC.

Purpose of the Study:

  • To review the progress of biomarkers for neoadjuvant immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
  • To summarize clinical trials involving neoadjuvant ICIs in NSCLC.
  • To highlight the significance of predictive biomarkers for identifying beneficiaries of neoadjuvant ICIs.

Main Methods:

  • Literature review of clinical trials on neoadjuvant ICIs in NSCLC.
  • Summary of disclosed clinical trial data.
  • Review of biomarker research associated with neoadjuvant ICI trials.

Main Results:

  • Neoadjuvant ICIs have shown higher downstage rates and pathological remission in NSCLC.
  • The identification of predictive biomarkers for neoadjuvant ICIs is still inconclusive.
  • Ongoing research focuses on developing reliable biomarkers for patient selection.

Conclusions:

  • Neoadjuvant ICIs represent a promising therapeutic strategy for resectable NSCLC.
  • Further research into predictive biomarkers is essential to optimize treatment efficacy and patient selection.
  • Biomarker discovery is critical for realizing the full potential of neoadjuvant immunotherapy in NSCLC.